OncoMatch/Clinical Trials/NCT06192849
To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Is NCT06192849 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Furmonertinib for non small cell lung cancer.
Treatment: Furmonertinib — This is a phase II, prospective, multi-centre study. To assess the efficacy and safety of furmonertinib in patients with epidermal growth factor receptor 20ins mutation positive stage IB-IIIA Non-small Cell Lung Carcinoma, following complete tumour resection with or without adjuvant chemotherapy. The study plans to enroll 20 subjects, treating with furmonertinib 160mg/d, until disease recurrence, death or intolerability. The maximum duration of treatment is three years. The primary endpoint is DFS. The secondary endpoint include DFS rate , OS and the change of HRQoL. In addition, the peripheral blood ctDNA will be collected and analyzed in this study
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR 20 insertion mutation
Patient with EGFR 20 insertion mutation diagnosed histologically or cytologically
Disease stage
Required: Stage IB, II, IIIA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anticancer therapy
Exception: excluding adjuvant platinum-based chemotherapy
Any prior anticancer therapy（excluding adjuvant platinum-based chemotherapy）
Lab requirements
Blood counts
Inadequate bone marrow reserve or organ function [excluded]
Kidney function
Inadequate bone marrow reserve or organ function [excluded]
Liver function
Inadequate bone marrow reserve or organ function [excluded]
Cardiac function
Mean resting corrected QT interval (QTc) >470 msec, obtained from 3 ECGs, using the screening clinic ECG Machine-derived QTc value; Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG; Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval
Inadequate bone marrow reserve or organ function; Mean resting corrected QT interval (QTc) >470 msec, obtained from 3 ECGs, using the screening clinic ECG Machine-derived QTc value; Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG; Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06192849 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR 20 insertion mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage IB or II or IIIA is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages